Related Experiment Video
Updated: Jun 8, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study
Emilia Fransvea1, Antonio Mazzocca, Angela Santamato
1Department of Internal Medicine, Immunology and Infectious Diseases, Section of Internal Medicine, University of Bari Medical School, Bari, Italy.
Purpose:
To identify the molecular mechanisms responsible for tumor cell migration is essential for developing agents that can prevent the relapse or the metastatic spread of hepatocellular carcinoma (HCC).
Methods:
In this study, we investigated the effects of the transforming growth factor-β receptor I inhibitor LY2109761 on two different human HCC cell lines, in vitro and in vivo.
Results:
LY2109761 inhibits HCC migration in a dose-dependent manner. This inhibition is associated with the decreased phosphorylation of SMAD-2, FAK and β1-integrin, and with increased levels of E-cadherin. By contrast, LY2109761 did not alter the phosphorylation pattern of p38MAPkinase. In a two- and a three-day time-course and in dose-titration experiments, LY2109761 inhibited HCC migration as well as phospho-SMAD-2 and the adhesion proteins. LY2109761 showed the best effect on day 2 at 1 nM and for 3 days at 100 nM concentration. This suggests that maximum effects were sustained for several days and were not dependent on excess concentrations. Finally, in a xenograft model of HCC, LY2109761 strongly inhibits tumor growth, intravasation and metastasis at the aforementioned lower concentrations.
Conclusions:
In conclusion, inhibition of transforming growth factor-β (TGF-β) appears to occur at low concentrations of LY2109761 that displays multiple effects on kinases that control HCC cell migration. These findings may help the design of future clinical trials with inhibitors of TGF-β.
Insights
The transforming growth factor-β receptor I inhibitor LY2109761 effectively reduces hepatocellular carcinoma (HCC) cell migration and metastasis. This drug shows promise for preventing HCC relapse and spread by targeting key molecular mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) metastasis is a major cause of cancer-related deaths.
- Understanding the molecular mechanisms of HCC cell migration is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the effects of the transforming growth factor-β (TGF-β) receptor I inhibitor LY2109761 on HCC cell migration.
- To identify the molecular targets and pathways affected by LY2109761 in HCC.
Main Methods:
- In vitro studies using two human HCC cell lines.
- In vivo studies using a xenograft model of HCC.
- Analysis of SMAD-2, FAK, β1-integrin, E-cadherin, and p38MAPkinase phosphorylation patterns.
Main Results:
- LY2109761 inhibited HCC cell migration in a dose-dependent manner.
- Inhibition was associated with decreased phosphorylation of SMAD-2, FAK, and β1-integrin, and increased E-cadherin levels.
- LY2109761 significantly inhibited tumor growth, intravasation, and metastasis in vivo at low concentrations.
Conclusions:
- Inhibition of TGF-β signaling by LY2109761 effectively reduces HCC cell migration and metastasis.
- LY2109761 targets multiple kinases involved in HCC cell motility.
- These findings support the potential clinical application of TGF-β inhibitors for HCC treatment.
Related Concept Videos
01:16TGF - β Signaling Pathway
01:07MAPK Signaling Cascades
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:24Regulation of Angiogenesis and Blood Supply